|Teva CEO Erez Vigodman|
11. Teva Pharmaceutical ($TEVA)
2014 revenue: $20.27 billion
2013 revenue: $20.314 billion
When it comes to overall revenue for Teva Pharmaceutical, things didn't change dramatically between 2013 and 2014. The Israeli drugmaker's $20.27 billion haul came in just below its $20.31 billion mark from the year prior. Nix the exchange-rate differences--which took a $346 million toll--and revenue inched up by 2%.
That could all be changing very soon, of course. For one, there's the fact that two knockoffs of lead Teva med Copaxone are currently awaiting FDA decisions; if their makers--Mylan ($MYL) and Natco Pharma, and Momenta ($MNTA) and Novartis' ($NVS) Sandoz--choose to launch at-risk, it could take a bite out of the $5.58 billion in revenue Teva gets from the drug, though at this stage analysts consider it unlikely.
More likely is that CEO Erez Vigodman comes through with one or more of the deals he's been promising since he took the helm early last year. One area he's looking to bulk up in is generics, in an effort to take the company back to its copycat roots. That segment of Teva's business dipped in 2014--from $9.90 billion to $9.81 billion--despite a 6% jump in the United States, where the company generates 45% of its generics revenues.
It was the ex-U.S. and Europe markets that dragged that generics mark down; ROW generics revenue sank 5% from 2013 to $2.2 billion. Not coincidentally, emerging markets is another area in which Vigodman says he'd like to make some pickups.
-- Carly Helfand (email | Twitter)
Should Teva buy Mylan? 'Close call,' analyst says
Cost-cutting, check. Now, it's on to dealmaking, Teva chief says
FDA puts off Mylan's Nexium generic, giving Teva's version free rein
Teva wins Copaxone SCOTUS appeal, but its patent battle won't stop there